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Introduction. Nontuberculous mycobacteria (NTMB) are 
widespread microorganisms which are capable of affecting 
both people with immunosuppression and healthy people. 
They have a wide range of virulence. For the first time 
these pathogens were identified in 1885. In 1950 
information that NTMB can cause pathological changes in 
the human body appeared. The genus Mycobacterium 
includes more than 150 species and 2 obligate pathogens 
(M. tuberculosis and M. leprae). Nontuberculous 
mycobacteria a lot of similar properties with pathogenic 
species and can cause pulmonary and extrapulmonary 
granulomatous lesions. Most patients who are infected 
with NTMB have background pulmonary diseases and / or 
immune system disorders. Often they are found on the 
background of chronic obstructive pulmonary disease 
(COPD), bronchiectasis, pneumoconiosis and have 
tuberculosis-like clinical signs. The incidence of 
nontuberculous mycobacterioses is growing rapidly 
worldwide, that's why they can become a serious problem 
for the health system soon [2-4]. This trend is especially 
noticeable in economically and socially developed 
countries, which have significantly reduced the burden of 
tuberculosis. Prevention of nontuberculous 
mycobacterioses is not developed that also significantly 
worsens the epidemic situation. 
In addition, there are factors that contribute to 
detection of nontuberculous mycobacterioses: 
 increasing the number of studied clinical samples 
 improvement of laboratory methods detection and 
identification of NTMB 
 recognition of NTMB as pathogens 
NTMB can be divided into groups according to the 
speed and character of growth. According to the speed of 
growth NTMB can be classified as following: 
 Slow-growing NTMB are growing for more than 14 
days and include M. avium complex (M. avium and M. 
intracellulare), M. kansasii, M. xenopi, M. simiae, M. 
szulgai, M. scrofulaceum, M. malmoense, M. terrae-
nonchromogenicum complex, M. haemophilum, and M. 
genavense. The optimal temperature for their growing is 
(except M. haemophilum which growth at 28-300С and M. 
xenopi which growth at 420С). Later other species of 
NTMB were isolated: M. celatum, M. interjectum, M. 
confluentis, M. triplex, M. lentiflavum, M. branderi, M. 
conspicuum, M. cookii, M. asiaticum. 
 NTMB with intermediate growth speed are growing for 
7-10 days and include M. marinum and M. gordonae. Their 
colonies are usually pigmented. The optimal temperature 
for M. marinum growth is 300С, for M. gordonae it is 350С. 
 Rapid-growing NTMB grow up to 7 days. M. fortuitum 
complex is the most widespread among them. It forms 
uncolored colonies. Also this group include M. chelonae 
subspecies, M. abscessus, M. mucogenicum, M. smegmatis 
Classification of NTMB based on character of colonies: 
 Non-chromogenic NTMB – cannot produce yellow 
pigment 
 Photochromogenic NTMB – produce NTMB under the 
light 
 Scotochromogenic NTMB – produce yellow pigment 
without light 
Although the species composition of NTMB 
depends on geographic location, M. avium complex 
(MAC) prevails everywhere, M. abscessus takes the 
second place, M. kansasii takes the third place [5]. 
First, tuberculosis and mycobacterioses were 
treated by the standard scheme of TB chemotherapy 
because of the similarity of their clinical picture, but later 
it was found that some NTMB have primary resistance to 
antituberculosis drugs. In addition, it was found that 
mycobacterioses require longer treatment (12 months after 
sputum conversion). Mycobacterioses treatment regimens 
depend on the form of the disease (pulmonary, 
disseminated, lesions of the skin and soft tissues, lesions of 
lymph nodes), the type of NTMB and its resistance. Drug 
susceptibility test for NTMB also remains difficult because 
some species (eg, MAC, M. kansasii, some rapid-growing 
NTMB) show different sensitivities to drugs in vitro and in 
vivo. Currently it's recommended to add fluoroquinolones 
to treatment regimens, because they demonstrate a better 
effectiveness in vivo than in vitro. According to the data 
obtained by T.F. Otten, levofloxacin (500 mg/day) is the 
most effective drug in the treatment of nontuberculous 
mycobacterioses. Treatment of nontuberculous 
mycobacterioses has limited therapeutic choices, is long 
and expensive and often is associated with several 
complications and interruption of treatment as a result. On 
the other hand the problem is amplified by the fact that 
existing recommendations for management of patients 
with mycobacteriosis are based primarily on expert opinion 
because of the lack of statistical data [6-9]. 
In the treatment of mycobacteriosis caused by M. 
avium complex clarithromycin was effective in 
combination with rifampicin and ethambutol, 
moxifloxacin in combination with clarithromycin was 
effective against M. kansasii [10]. 
Another important question still is criteria for 
differentiation of mycobacteriosis as a disease from finding 
NTMB as saprophytes, and thus - the need for treatment. 
Therefore, the decision to start treatment is a complex and 
individualized process when all "pluses" and "minuses" 
must be weighed. 
Despite the fact that in Ukraine as well as 
worldwide there is growing incidence of nontuberculous 
mycobacterioses, there are still no standardized protocols 
of diagnosis and treatment of mycobacterioses in our 
country, which makes impossible prescribing of adequate 
chemotherapy and worsens the prognosis. 
Aim. To analyze the effectiveness of chemotherapy 
regimens for patients with nontuberculous mycobacteriosis 
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who were registered in Kharkiv region and its dependence 
on the character of growth of NTMB. 
 
Materials and methods.  
We have retrospectively studied medical histories 
of 26 patients (5 women and 21 men of average age - 38 ± 
15 years) in whom tuberculosis wos diagnosed by the 
results of X-ray and sputum microscopy during 2014-2016. 
To confirm the diagnosis, patients were examined by 
diagnostic algorithm, approved by Order №620 of 
Ukrainian Ministry of Health  from 09.04.2014, which 
included chest X-ray, double microscopic examination of 
sputum, sputum culture in system BACTEC and on 
Lowenstein-Jensen media, molecular-genetic test 
(GeneXpert MTB / RIF) and routine laboratory tests. 
Nontuberculous mycobacteriosis was diagnosed basing on 
growth of NTMB in system BACTEC and then it was 
verified by the following criteria: 
 Microscopy: absence of Cord-factor formation (NTMB 
are located “loose” in smear) 
 Negative immunochromatographic test (ID-test) 
 Negative GeneXpert MTB/RIF 
Then obtained NTMB were identified for likely 
pathogens on the basis of Runyon classification and 
modified classification, approved by Ukrainian Ministry of 
Health No 45 from 06.02.2002, in which the NTMB 
growth rate, nature and color of the colonies were taken 
into account. 
As a result of research it was determined that 17 
patients had chromogenic NTMB with slow growth and 9 
patients - non-chromogenic NTMB with slow growth 
(Table. 1) 
 
Table 1 –Distribution of pathogens 
Group of mycobacteria Number 
Slow-growing chromogenic NTMB 
(M. kansasii, M.gordonae, M. marinum) 
17 (65,4%) 
Slow-growing non-chromogenic NTMB 
(M. avium, M. intracellulare, M.xenopi) 
9 (34,6%) 
Standard regimens of antituberculosis 
chemotherapy were prescribed to all the patients: 
 2HRZE – standard scheme for treatment of susceptible 
TB – 16 patients 
 2R(Rfb)Z(E)LfxKm – individual scheme – 6 patients 
 2R(Rfb)Z(E)LfxClr – individual scheme – 2 patients 
where R – Rifampicin, Rfb – Rifabutin, де R – 
рифампіцин, Rfb – рифабутін, Z – Pyrazinamide, E – 
Ethambutol, Lfx – Levofloxacin, Clr – Clarithromycin, 
Km – Kanamycin. These schemes predicted daily 
administration of drugs, the analysis was carried out in 2 
months. Apparently, this schemes differed from those 
proposed by CDC (Table. 2) [11-13]. 
 
Table 2 – Schemes proposed by CDC for treatment of nontuberculous mycobacterioses 
NTMB Treatment 
M. avium complex Clarithromycin or azithromycin 
+ ethambutol  
+ rifampicin 
M. abscessus 1 macrolide  
+ 1 parenteral drug (amikacin, cefoxitin, imipenem) 
M. kansasii Isoniazid 
+ ethambutol  
+ rifampicin 
M. marinum Clarithromycin or azithromycin or doxycycline, or trimethoprim-sulfamethoxazole 
+ ethambutol  
+ rifampicin 
M. xenopi Clarithromycin  
+ ethambutol  
+ rifampicin  
± fluoroquinolone 
M. fortuitum  2 drugs, which set the sensitivity NTMB from the following list: 
 tobramycin 
 cefoxitin  
 meropenem 
 levofloxacin 
At the end of two months of treatment we have 
evaluated laboratory parameters of recovery (sputum 
conversion) and positive clinical and radiologic dynamics 
(disappearance or reduction in severity of intoxicational 
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and local complaints, healing of cavities, resorption and 
consolidation of infiltrates). 
According to the experts' opinion, the absence of 
acid-fast bacilli in sputum smear is the most important 
indicator of treatment effectiveness because clinical and 
radiographic dynamics is relatively slow. 
 
Results and discussion.  
Standard chemotherapy of tuberculosis by category 
1 (2 HRZE) was prescribed the most often in patients with 
chromogenic slow-growing NTMB (70.6%). This scheme 
was not too effective, because at the sputum conversion 
was observed only in 83.3% of patients to the end of the 
second month of treatment, positive clinical and 
radiological dynamics occurred only in 41.7% of patients. 
However, in patients receiving individual scheme (2R 
(Rfb) Z (E) LfxKm) we observed fast positive clinical and 
radiological dynamics and sputum conversion by the end 
of the second month. Substitution of kanamycin with 
clarithromycin in 1 patient did not give a positive effect. 
In patients with slow-growing non-chromogenic 
NTMB all the 3 schemes were effective. We obtained 
expressed positive clinical and radiographic dynamics, 
disappearance of intoxication, sputum conversion, 
significant resorption and consolidation of foci in lung 
tissue, healing of cavities. 
It should be noted that 2 patients (1 in each group) 
have abandoned the treatment but follow-up they we have 
recorded self-recovery in them. 
 
Table 3 – Results of patients’ treatment 
Treatment regimens Slow-growing chromogenic NTMB Slow-growing non-chromogenic NTMB 
2HRZE/4HR 12 (70,6%)  4 (44,44%)  
Laboratory recovery 10 (83,3%) 4 (100,0%)  
Clinical and radiological 
recovery 
5 (41,7%)  
 
3 (75,0%)  
2R(Rfb)Z(E)LfxKm 
/10RELfx 
3 (17,6%)  3 (33,3%)  
Laboratory recovery 3 (100,0%) 3 (100,0%)  
Clinical and radiological 
recovery 
3 (100,0%)  2 (66,7%)  
2R(Rfb)Z(E)LfxClr/ 
10RlfxClr 
1 (5,9%)  1 (11,1%)  
Laboratory recovery 0  1  (100%)  
Clinical and radiological 
recovery 
0  1 (100%) 
Self-healing 1 (5,9%) 1 (11,1%)  
Conclusions. Thus we have seen a significant 
prevalence of chromogenic slow-growing NTMB among 
isolated mycobacteria. Individual treatment regimens with 
the addition of fluoroquinolones and aminoglycosides 
were effective for them. All the 3 treatment regimens were 
effective in patients with non-chromogenic slow-growing 
NTMB which allows us to use in them standard 
chemotherapy regimen with first-line anti-TB drugs, which 
in turn will save in this category of patients time and 
money. 
The problem of mycobacterioses is not still well 
understood by pulmonologists. Until now, many patients 
with nontuberculous mycobacterioses obtain treatment 
with a diagnosis of "tuberculosis" or are observed over a 
number of chronic lung diseases. Situation is also 
complicated with clinical and radiological similarities of 
mycobacterioses and tuberculosis. And in addition timely 
detection of NTMB is complicated with widespread belief 
that mycobacterioses affect only people with 
immunosuppression. 
International experts say that we have to develop 
and implement reliable methods to identify the species 
NTMB for successful treatment because treatment regimen 
should be individualized and based on NTMB sensitivity 
to drugs. It is also necessary to put into practice strict 
criteria and algorithms to choose treatment regimen and 
select patients for surgical treatment [14]. 
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ANALYSIS OF THE EFFECTIVENESS OF 
INDIVIDUALIZED TREATMENT REGIMENS FOR 
NONTUBERCULOUS MYCOBACTERIOSES 
Shevchenko O.S., Kalmykova I.M., Novohatska M.F., 
Shyrapova O.V., Pogorelova O.O. 
Despite the fact that in Ukraine, as well as worldwide the 
incidence of nontuberculous mycobacterioses is growing, 
in our country there are still no standardized protocols for 
their diagnosis and treatment, which makes it impossible 
to prescribe adequate chemotherapy and worsens the 
prognosis of treatment. We have retrospectively studied 
medical histories of 26 patients who were diagnosed with 
"pulmonary non-tuberculous mycobacteriosis" during 
2014-2016. The diagnosis of "non-tuberculous 
mycobacteriosis" was established based on the growth of 
non-tuberculous mycobacteria (NTMB) in BACTEC 
system, and then verified by the absence of Cord-factor 
formation, negative immunochromatographic test, 
negative GeneXpert MTB / RIF. Based on the results of 
the studies, it was determined that 17 patients had slow-
growing chromogenic NTMB and 9 patients had slow-
growing non-chromogenic NTMB. With the use of 
2HRZE regimen, 83.3% of patients with slow-growing 
chromogenic NTMB underwent laboratory recovery, and 
only 41.7% of patients had clinical and X-ray recovery. 
However, patients who received the individual regimen 
(2R(Rfb)Z(E)LfxKm) had a rapid positive dynamics, 
clinical, radiological and laboratory recovery until the end 
of intensive phase. In patients with slow-growing non-
chromogenic NTMB, all three regimens (2HRZE, 
2R(Rfb)Z(E)LfxKm, 2R(Rfb)Z(E)LfxClr) proved to be 
effective. We believe that it is necessary to improve level 
of identification of NTMB for the timely appointment of 
an adequate chemotherapy regimen.  
Keywords. Nontuberculosis mycobacterium, 
chemotherapy,  
 
